Work

Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells

Year: 2015

Type: article

Abstract: Toll-like receptor (TLR) agonists are potent immunostimulatory agents that have demonstrated great potential for cancer immunotherapy. We have genetically-engineered tumor-specific T cells to deliver and secrete the TLR5 ligand (TLR5L) flagellin to the tumor site to provide costimulation for antitumor immune activity. We found that TLR5L-secreting T cells offered a therapeutic benefit by altering several aspects including augmenting T cell effector function and expansion as well as reshaping the tumor microenvironment toward one that enhances antitumor T cell responses.

Source: OncoImmunology

DOI: 10.1080/2162402x.2015.1076609

Authors: Sabina Kaczanowska, Eduardo Davila

Institutions: University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913